This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
scPharmaceuticals (SCPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of -8% and 62.29%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?
by Zacks Equity Research
Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of 5.33% and 24.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of 7.25% and 121.60%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Merck (MRK) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 4.67% and 0.65%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of -38.89% and 2.17%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study
by Zacks Equity Research
Celldex stock falls due to safety concerns related to the treatment of urticaria patients with barzolvolimab in a phase II study, despite robust efficacy data.
Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of 8.47% and 121.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Acadia Healthcare (ACHC) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Acadia Healthcare (ACHC) delivered earnings and revenue surprises of 3.41% and 1.54%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Celldex (CLDX) points to an 87.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 67.8% upside potential for Celldex (CLDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Celldex (CLDX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy
by Zacks Equity Research
Celldex (CLDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
by Zacks Equity Research
Celldex (CLDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 71.8% upside potential for Celldex (CLDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Celldex (CLDX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Celldex (CLDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Predict a 26.53% Upside in Celldex (CLDX): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26.5% in Celldex (CLDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Journey Medical (DERM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
When Journey Medical (DERM) reports fourth-quarter 2023 results, investors will likely focus on the top and bottom-line numbers.
Celldex Therapeutics (CLDX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of 25% and 245.77%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) to Report Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
Viatris' (VTRS) Q4 results are likely to gain from momentum in its branded and generic businesses.
Can Higher Costs Affect Elevance Health's (ELV) Q4 Earnings?
by Zacks Equity Research
Elevance Health's (ELV) fourth-quarter results are likely to reflect higher premiums and product revenues.
Can UnitedHealth's (UNH) UnitedHealthcare Unit Aid Q4 Earnings?
by Zacks Equity Research
UnitedHealth's (UNH) fourth-quarter results are expected to benefit from an increase in UnitedHealthcare's Medicare & Retirement revenues as well as the number of people it served.